PTSD affects roughly 13 million adults in the United States and has seen only two FDA-approved medications in decades. For most of this year, the pharmaceutical psychedelic story in this indication has belonged to one company: Resilient Pharmaceuticals, whose MDMA-assisted therapy program carries the field’s longest clinical history and its most consequential rejection. That is no longer the whole story. Compass Pathways now has its own late-stage psilocybin program in the same indication, cleared by FDA for a pivotal trial and building on clinical groundwork distinct from Resilient’s.
What Redefine is
The Redefine Study, registered on ClinicalTrials.gov as NCT07570654 under sponsor protocol COMP202, is a randomized Phase 2b/3 trial evaluating COMP360 psilocybin for PTSD, and FDA accepted the Investigational New Drug application enabling it in January. That clearance followed a completed open-label Phase 2 safety and tolerability study, 22 participants, no serious adverse events, meeting both its primary safety endpoint and its secondary efficacy measures, with rapid and durable symptom improvement observed out to twelve weeks, published in the Journal of Psychopharmacology. Compass has also published a more granular analysis of how those PTSD sessions were run, reporting that 78 percent of the administration session was spent in silence, minimal, non-directive support rather than active therapeutic intervention, a detail the company has framed as evidence its support model is standardized and reproducible across both its PTSD and TRD programs. Compass has not released the underlying session data for independent review.
How that compares to where Resilient stands
Resilient’s MDMA program holds a fundamentally different evidentiary position. Its two completed Phase 3 trials, run under MAPS and later Lykos, remain the largest dataset in this drug class by participant count, and the FDA’s 2024 rejection identified specific deficiencies, incomplete adverse event collection, insufficient durability data, and functional unblinding compounded by high rates of prior MDMA use among participants. This desk has covered Resilient’s reported resubmission, filed in August without a new Phase 3 trial, as a bet that argument and reinterpretation of existing data can answer those deficiencies rather than new evidence generated specifically to address them.
Compass is running the opposite experiment, for a different compound entirely. Its PTSD program is earlier in absolute terms, an open-label Phase 2 rather than a completed Phase 3, but its evidentiary posture going into pivotal testing is cleaner: no FDA rejection to answer for, no documented history of adverse event undercollection, and a trial design informed directly by the same FDA guidance this desk examined in July, including attention to the functional unblinding problem that has proven costly for other sponsors in this drug class.
Why this matters beyond either company
Two pharmaceutical sponsors pursuing FDA approval in the same indication, using different psychedelic compounds and arriving by different evidentiary routes, gives PTSD a real comparative test case this drug class has not had before. If Compass’s pivotal trial reads out cleanly, in an indication where its main competitor’s history includes a well-documented rejection, that outcome would say something specific about whether Resilient’s difficulties reflected the MDMA molecule, the trial design MAPS ran a decade ago, or PTSD as an indication generally, three explanations this desk has not been able to fully separate until now. A second sponsor succeeding where the first stumbled would point toward trial design and evidentiary rigor as the deciding factor, not the underlying drug class or indication.
A dissenting view worth weighing alongside the momentum
Not every credentialed voice in this field reads the pace of expansion the same way. Steve Kisely, a psychiatrist and psychiatric epidemiologist who now edits the Australian and New Zealand Journal of Psychiatry and has published repeated, sustained criticism of rapid psychedelic policy expansion there since at least 2023, including his widely cited argument that Australia’s own down-scheduling of MDMA and psilocybin moved too fast and too soon, continues to argue this year for caution over acceleration in how psychedelic-assisted therapy expands. Kisely’s specific critique of Australia’s regulatory experience, that the country’s drug regulator proceeded despite its own commissioned research recommending against the change, is a pointed reminder that regulatory momentum and evidentiary adequacy are not the same thing, a distinction directly relevant to how Compass’s and Resilient’s parallel PTSD bets should be read.
The caveats
Compass’s PTSD program remains earlier-stage than its TRD program in absolute regulatory terms, an FDA-cleared pivotal trial rather than a program already under NDA review, and pivotal trial data can diverge meaningfully from open-label Phase 2 results, a gap this desk has tracked closely across other sponsors in this drug class. Resilient’s resubmission remains reported rather than confirmed through a primary company or FDA source, as this desk has noted in prior coverage. And Compass’s own characterization of its standardized, low-touch support model as a competitive advantage is company framing that has not yet been tested against a comparator trial designed to isolate that specific variable.
The frame
PTSD has functioned as a single-company story in psychedelic pharmaceutical development for long enough that Resilient’s specific history, one rejection, one resubmission, has often stood in for what the entire indication and drug class can or cannot achieve. That framing no longer holds cleanly. A second, differently positioned sponsor entering pivotal testing in the same indication means the next several quarters offer something this desk has not had before in PTSD specifically: a real comparison point for whether regulatory success in this indication depends on the specific evidentiary rigor a trial brings to the FDA, rather than on anything intrinsic to psychedelic-assisted therapy as an approach. Kisely’s caution is a useful reminder that neither company’s outcome should be read as settling that question until the pivotal data exists to settle it.